Literature DB >> 18925697

Immunohistochemically detected high expression of matrix metalloproteinase-2 as predictor of poor prognosis in Duke's B colon cancer.

Zeljko Sundov1, Snjezana Tomić, Katarina Vilović, Nenad Kunac, Marija Kalebić, Josko Bezić.   

Abstract

AIM: To demonstrate immunohistochemical expression of matrix metalloproteinase-2 (MMP-2) protein in Duke's B colon cancer and determine its correlation with age, sex, grade, presence of vascular invasion, and patients' overall survival.
METHOD: The study took place from January 1995 to December 1997. We determined the expression of MMP-2 in 152 formalin-fixed, paraffin embedded specimens of Duke's B colon carcinomas by immunohistochemical analysis using MMP-2 monoclonal antibody. Immunohistochemical expression was scored semiquantitatively. Carcinomas were graded as low or high grade. Survival time was analyzed with Kaplan-Meier method, and the log-rank test was used to assess the differences between groups. Cox proportional hazard regression model was used for multivariate survival analysis. RESULT: Univariate analysis showed that positive staining for MMP-2, high histological grade, vascular invasion, male sex, and age>60 years were associated with shorter survival in patients with Duke's B colon cancer (P range from 0.023 to <0.001). Multivariate analysis showed that only MMP-2 overexpression (P<0.001; hazard ratio [HR]=3.64) and vascular invasion (P<0.001; HR=4.27) were associated with shorter overall survival.
CONCLUSION: Expression of MMP-2 is an important independent indicator of shorter survival in patients with Duke's B colon cancer and should be taken into consideration in decision-making on the use of adjuvant systemic therapy in patients with Duke's B colon cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18925697      PMCID: PMC2582356          DOI: 10.3325/cmj.2008.5.636

Source DB:  PubMed          Journal:  Croat Med J        ISSN: 0353-9504            Impact factor:   1.351


  27 in total

1.  Cancer statistics, 2005.

Authors:  Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2005 Jan-Feb       Impact factor: 508.702

Review 2.  The role of gelatinases in colorectal cancer progression and metastasis.

Authors:  Olaf R F Mook; Wilma M Frederiks; Cornelis J F Van Noorden
Journal:  Biochim Biophys Acta       Date:  2004-12-17

3.  Relevance of biologic markers in colorectal carcinoma: a comparative study of a broad panel.

Authors:  Chiara Barozzi; Matteo Ravaioli; Antonia D'Errico; Gian Luca Grazi; Gilberto Poggioli; Giulia Cavrini; Alighieri Mazziotti; Walter Franco Grigioni
Journal:  Cancer       Date:  2002-02-01       Impact factor: 6.860

Review 4.  American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer.

Authors:  Al B Benson; Deborah Schrag; Mark R Somerfield; Alfred M Cohen; Alvaro T Figueredo; Patrick J Flynn; Monika K Krzyzanowska; Jean Maroun; Pamela McAllister; Eric Van Cutsem; Melissa Brouwers; Manya Charette; Daniel G Haller
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

Review 5.  Tumor invasion and metastasis: an imbalance of positive and negative regulation.

Authors:  L A Liotta; W G Stetler-Stevenson
Journal:  Cancer Res       Date:  1991-09-15       Impact factor: 12.701

6.  Prognostic significance of matrix metalloproteinase-2, cathepsin D, and tenascin-C expression in colorectal carcinoma.

Authors:  Banu Sis; Ozgul Sağol; Ali Küpelioğlu; Selman Sokmen; Cem Terzi; Mehmet Fuzun; Erdener Ozer; Paul Bishop
Journal:  Pathol Res Pract       Date:  2004       Impact factor: 3.250

Review 7.  Colorectal carcinoma: diagnostic, prognostic, and molecular features.

Authors:  Carolyn C Compton
Journal:  Mod Pathol       Date:  2003-04       Impact factor: 7.842

8.  Gender-related survival differences associated with EGFR polymorphisms in metastatic colon cancer.

Authors:  Oliver A Press; Wu Zhang; Michael A Gordon; Dongyun Yang; Georg Lurje; Syma Iqbal; Anthony El-Khoueiry; Heinz-Josef Lenz
Journal:  Cancer Res       Date:  2008-04-15       Impact factor: 12.701

9.  Correlation between expression of matrix metalloproteinase-2 (MMP-2), and matrix metalloproteinase-9 (MMP-9) and angiogenesis in colorectal adenocarcinoma.

Authors:  T S Kim; Y B Kim
Journal:  J Korean Med Sci       Date:  1999-06       Impact factor: 2.153

10.  Expression of tissue inhibitor of metalloproteinases TIMP-2 in human colorectal cancer--a predictor of tumour stage.

Authors:  P Ring; K Johansson; M Höyhtyä; K Rubin; G Lindmark
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more
  4 in total

1.  Matrix metalloproteinase 2 overexpression and prognosis in colorectal cancer: a meta-analysis.

Authors:  Mumu Shi; Bo Yu; Hongguo Gao; Jingwen Mu; Changwei Ji
Journal:  Mol Biol Rep       Date:  2012-11-27       Impact factor: 2.316

2.  Matrix metalloproteinase-2 and -7 expression in colorectal cancer.

Authors:  Seong Woo Hong; Yun Kyung Kang; Byungmo Lee; Woo Yong Lee; Yeo Gu Jang; In Wook Paik; Hyucksang Lee
Journal:  J Korean Soc Coloproctol       Date:  2011-06-30

Review 3.  The role of the cell-cell interactions in cancer progression.

Authors:  Katarzyna Kamińska; Cezary Szczylik; Zofia F Bielecka; Ewa Bartnik; Camillo Porta; Fei Lian; Anna M Czarnecka
Journal:  J Cell Mol Med       Date:  2015-01-19       Impact factor: 5.310

4.  No associations of a set of SNPs in the Vascular Endothelial Growth Factor (VEGF) and Matrix Metalloproteinase (MMP) genes with survival of colorectal cancer patients.

Authors:  Lydia A Dan; Salem Werdyani; Jingxiong Xu; Konstantin Shestopaloff; Angela Hyde; Elizabeth Dicks; Ban Younghusband; Jane Green; Patrick Parfrey; Wei Xu; Sevtap Savas
Journal:  Cancer Med       Date:  2016-06-23       Impact factor: 4.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.